Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI.
Department of Statistics, University of Michigan, Ann Arbor, MI.
Hepatology. 2018 Sep;68(3):872-882. doi: 10.1002/hep.29887. Epub 2018 May 20.
Alcoholic cirrhosis (AC) is a major cause of liver-related morbidity and mortality in the United States. Rising rates of alcohol use disorders in the United States will likely result in more alcoholic liver disease. Our aim was to determine the prevalence, health care use, and costs of AC among privately insured persons in the United States. We collected data from persons aged 18-64 with AC (identified by codes from the International Classification of Diseases, Ninth and Tenth Revisions) enrolled in the Truven MarketScan Commercial Claims and Encounters database (2009-2015). We determined yearly prevalence, weighted to the national employer-sponsored, privately insured population. Using competing risk analysis, we estimated event rates for portal hypertensive complications and estimated the association between AC and costs as well as admissions and readmissions. In 2015, 294,215 people had cirrhosis and 105,871 (36%) had AC. Mean age at AC diagnosis was 53.5 years, and 32% were women. Over the 7 years queried, estimated national cirrhosis prevalence rose from 0.19% to 0.27% (P < 0.001) and for AC from 0.07% to 0.10% (P < 0.001). Compared to non-AC, AC enrollees were significantly more likely to have portal hypertensive complications at diagnosis and higher yearly cirrhosis and alcohol-related admissions (25 excess cirrhosis admissions and 6.3 excess alcohol-related admissions per 100 enrollees) as well as all-cause readmissions. Per-person costs in the first year after diagnosis nearly doubled for AC versus non-AC persons (US$ 44,835 versus 23,319).
In a nationally representative cohort of privately insured persons, AC enrollees were disproportionately sicker at presentation, were admitted and readmitted more often, and incurred nearly double the per-person health care costs compared to those with non-AC. (Hepatology 2018).
在美国,酒精性肝硬化(AC)是与肝脏相关的发病率和死亡率的主要原因。美国酗酒障碍发病率的上升可能会导致更多的酒精性肝病。我们的目的是确定美国私人保险人群中 AC 的患病率、医疗保健利用和费用。我们从患有 AC(通过国际疾病分类,第九和第十修订版的代码识别)的 18-64 岁人群中收集数据,这些人参加了 Truven MarketScan 商业索赔和就诊数据库(2009-2015 年)。我们确定了每年的患病率,并对全国雇主赞助的私人保险人群进行了加权。使用竞争风险分析,我们估计了门脉高压并发症的事件发生率,并估计了 AC 与费用以及入院和再入院之间的关联。2015 年,有 294215 人患有肝硬化,其中 105871 人(36%)患有 AC。AC 诊断时的平均年龄为 53.5 岁,32%为女性。在调查的 7 年中,全国肝硬化患病率从 0.19%上升到 0.27%(P < 0.001),AC 患病率从 0.07%上升到 0.10%(P < 0.001)。与非 AC 患者相比,AC 患者在诊断时更有可能患有门脉高压并发症,并且每年肝硬化和酒精相关的入院率更高(每 100 名患者中有 25 例肝硬化入院和 6.3 例酒精相关入院),以及全因再入院率。与非 AC 患者相比,AC 患者在诊断后第一年的人均医疗费用几乎翻了一番(44835 美元对 23319 美元)。
在一个具有全国代表性的私人保险人群队列中,AC 患者的病情明显更严重,入院和再入院的次数更多,并且与非 AC 患者相比,人均医疗保健费用几乎增加了一倍。(Hepatology 2018)。